CEO Gordon Sanghera on Innovation and the future of diagnostics
Mon 15th May 2017
At the recent London Calling talk, Gordon Sanghera opened the second day of the conference with views on how a company should approach disruptive technology development and innovation.
He also spoke about how nanopore technology could change diagnostics, particularly in infectious disease. Oxford Nanopore is currently developing the 'Flongle', a 'Flow Cell Dongle' that adapts the MinION Flow cell with a low cost, reusable chip that will be particularly well suited to people who need larger numbers of individual, low cost DNA analyses while still retaining the unique real-time, ultra-long read properties of nanopore sequencing.